BiVictriX Therapeutics Plc (LON:BVX) Insider Robert Edward Hawkins Purchases 20,000 Shares

BiVictriX Therapeutics Plc (LON:BVX) insider Robert Edward Hawkins bought 20,000 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were purchased at an average cost of GBX 7 ($0.09) per share, for a total transaction of £1,400 ($1,840.89).

BiVictriX Therapeutics Stock Performance

LON:BVX opened at GBX 7.41 ($0.10) on Tuesday. The company has a 50-day moving average of GBX 11.30 and a 200-day moving average of GBX 11.44. The firm has a market cap of £6.12 million, a price-to-earnings ratio of -185.25 and a beta of -0.60. The company has a current ratio of 4.40, a quick ratio of 7.49 and a debt-to-equity ratio of 8.81. BiVictriX Therapeutics Plc has a twelve month low of GBX 7 ($0.09) and a twelve month high of GBX 15.30 ($0.20).

BiVictriX Therapeutics Company Profile

BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours.